@article{ref1,
title="Efficacy and tolerability of long-term aripiprazole treatment in a patient with bipolar I disorder",
journal="Italian journal of psychopathology",
year="2009",
author="De Berardis, D. and Serroni, N. and Campanella, D. and Moschetta, F.S. and Ferro, F.M.",
volume="15",
number="1",
pages="99-101",
abstract="Aripiprazole is an atypical antipsychotic with partial dopamine D 2 and 5-HT1A agonist activity and potent antagonist activity at the 5-HT2A receptor. It also displays low affinity for H1-histaminergic, muscarinic, and cholinergic receptors. This pharmacologic profile has been associated with a lower potential for extrapyramidal side effects, weight gain, and sedation. For aripiprazole, therapeutic efficacy in bipolar disorder has been reported. However it is unclear whether aripiprazole may be helpful in the treatment of patients who have not responded to other atypical antipsychotics and with severe suicidal ideation. In the present report, we describe a case of a patient with BD successfully treated with aripiprazole, after multiple unsatisfactory pharmacological treatments.<p /><p>Language: it</p>",
language="it",
issn="1592-1107",
doi="",
url="http://dx.doi.org/"
}